SecBot SecBot

VKTX drug pipeline

Viking Therapeutics, Inc. · 4 rated drugs
$26.80
−8.3% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
4
1 bearish · 3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 3
Time to marketUnknown; Phase 3 trials (SUNRISE-1/2) were initiated October 2026. If successful, potential FDA submission could come in 2028-2029 at the earliest, barring accelerated development.

VK2735 Updated Oct 24

What to watch

The key near-term catalyst is Q3 2026 earnings on Oct 28, 2026, where management may provide Phase 3 timeline updates. The Phase 3 SUNRISE-1/2 trials were just initiated in Oct 2026, so topline data is likely 18-24+ months away. With the stock at ~$24.40 near 52-week lows and the mean analyst target at ~$95, the risk/reward hinges on whether Phase 3 data mirrors the strong Phase 2 results, but significant capital dilution (~$575M raise in Sept 2026) has already weighed on shares.

Bull case
  • VK2735 is a dual GLP-1/GIP receptor agonist (same mechanism as Eli Lilly's blockbuster tirzepatide) that has already demonstrated promising Phase 2 weight-loss data, supporting an oral Phase 3 program (SUNRISE-1 and SUNRISE-2) initiated in October 2026.
  • Analyst consensus is overwhelmingly bullish: 23 Buy/Strong Buy ratings vs 3 Hold, zero Sells, with a mean price target of ~$95.05 against the current ~$24.40 stock price, implying roughly 290% upside.
  • The company raised ~$575M in gross proceeds in Sept 2026 specifically to fund VK2735's Phase 3 development and potential commercialization, removing near-term financing risk.
Bear case
  • VK2735 enters a massive competitive market already dominated by Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro/tirzepatide), which target the same dual GLP-1/GIP mechanism, VK2735 will need to show best-in-class data to carve out market share.
  • The stock has fallen from $43.15 52-week high to $24.40 (near 52-week low) as of Oct 23, 2026, and a ~$575M capital raise via convertible notes and common stock in Sept 2026 has diluted existing shareholders significantly, with a $50.75/share note conversion price creating overhang.
  • Short interest is high at roughly 20.62% of estimated shares outstanding as of Sept 30, 2026, and the bull/bear evidence scan shows a net bearish signal with 16+ institutional exits/trims and ~$5M in insider sales by the CEO and CFO in July 2026.
● neutral
Impact
PhasePhase 1b/2a (completed)
Time to marketUnknown; no Phase 2b or pivotal trial has been announced. If a Phase 2b/3 program were started in 2027, potential approval would be several years away (likely 2029-2031 at the earliest).

VK0214 Updated Oct 24

What to watch

VK0214 is not a near-term value driver for VKTX. Investors should focus on Viking's obesity pipeline, particularly the Phase 3 VK2735 program, for material catalysts. VK0214 may become relevant only if it advances to a registrational trial, which has not been announced. The stock's direction is dominated by obesity drug readouts, not this orphan program.

Bull case
  • Orphan Drug Designation from FDA provides regulatory incentives and 7-year market exclusivity upon approval
  • Positive Phase 1b/2a biomarker data showing VLCFA reductions suggest proof-of-mechanism in X-ALD
  • X-ALD is a serious, life-shortening rare disease with limited treatment options, representing significant unmet need
Bear case
  • VK0214 is a low-priority program within Viking's pipeline, the company is focused on its obesity assets (VK2735, VK3019) which consume nearly all R&D spending and management attention
  • No Phase 2b or Phase 3 trial has been announced, and timelines are uncertain with no catalyst on the horizon
  • VK0214 is dwarfed by competition for investor mindshare; the stock's movements are driven entirely by obesity drug data, not this orphan program
▼ bearish
Impact
PhasePhase 2 (completed/on hold)
Time to marketUnknown; the program is in legal limbo due to a license dispute.

VK2809 Updated Oct 24

What to watch

VK2809 is not a near-term catalyst for VKTX. Investors should monitor the Ligand license dispute for resolution, but the real value driver for the stock is the VK2735 obesity program. The $534M capital raise in September 2026 was explicitly earmarked for VK2735 and VK3019, not VK2809.

Bull case
  • Thyroid hormone receptor beta agonists have shown promise in reducing liver fat in NASH patients, a large unmet medical need with few approved treatments.
  • If the Ligand license dispute is resolved in Viking's favor, the program could be revived and potentially partnered or advanced.
Bear case
  • Ligand terminated the TR-Beta Program license in April 2026, alleging Viking materially breached its development obligations, legal uncertainty clouds the program's future.
  • Viking has clearly deprioritized VK2809, focusing capital on VK2735 (obesity Phase 3) and VK3019 (amylin); the $534M capital raise in Sept 2026 was designated for those programs, not VK2809.
  • VK2809 faces competition from Madrigal's Rezdiffra (resmetirom), the first FDA-approved TR-β agonist for NASH, which is already on the market.
● neutral
Impact
PhasePreclinical / Early-stage (no confirmed Phase 1/2 clinical trials identified)
Time to marketNot stated

VK3019 Updated Oct 24

What to watch

VK3019 is preclinical/early-stage and not the company's primary value driver, investors should watch Viking's lead asset VK2735 (Phase 3 obesity) for near-term stock movement. VK3019 updates would most likely come via Viking's R&D day or quarterly earnings calls. The next company catalyst is Q3 2026 earnings on October 28, 2026, where pipeline updates on both VK2735 and VK3019 may be discussed.

Bull case
  • Amylin agonists represent a differentiated mechanism in obesity, amylin promotes satiety, complements GLP-1 agonism, and could offer weight loss with fewer gastrointestinal side effects or be used as a combination agent.
  • Viking's lead asset VK2735 (GLP-1/GIP dual agonist) has shown strong Phase 2/3 data, validating the company's metabolic drug discovery platform, success could derisk VK3019 as a pipeline-in-progression story.
  • Viking raised ~$534M in September 2026 specifically to fund VK3019 development alongside VK2735 commercialization, signaling strong institutional confidence in the pipeline.
Bear case
  • As an early-stage/preclinical asset, VK3019 has a high probability of never reaching the market, most early-stage metabolic drugs fail in clinical trials.
  • VK3019 would enter a fiercely competitive obesity market dominated by Novo Nordisk's Wegovy/Ozempic, Eli Lilly's Zepbound/Mounjaro, and numerous other amylin and GLP-1 agonists in development.
  • Viking has no approved products and is pre-revenue, any VK3019 development costs are fully funded by equity/debt raises that dilute existing shareholders, as seen in the Sep 2026 ~$534M capital raise.